Quanvia provides quantum sensing platforms that use nitrogen‑vacancy (NV) centers in diamond to detect disease biomarkers with sub‑pico‑molar sensitivity. The compact assay modules convert magnetic resonance signals from target molecules into optical fluorescence readouts, delivering rapid, quantitative results without extensive sample preparation.
Funding
Funding not disclosed
Founders
Product
Problem
Current biomarker detection methods often lack the sensitivity required to identify disease‑related molecules at ultra‑low concentrations, limiting early diagnosis and detailed research analysis.
Solution
Quanvia offers quantum sensing platforms that leverage nitrogen‑vacancy (NV) centers in diamond to achieve unprecedented sensitivity for biomarker detection. The NV‑center sensors are integrated into compact assay formats, enabling non‑invasive, high‑precision measurement of trace disease markers in biomedical and clinical laboratory settings. By converting magnetic resonance signals from target molecules into optical readouts, the technology provides rapid, quantitative results without the need for extensive sample preparation. This approach supports early diagnostic workflows and advanced research applications where detecting minute biomarker levels is critical.
Target Audience
Primary customers are clinical diagnostic laboratories, biomedical research facilities, and pharmaceutical development teams that require ultra‑sensitive detection of disease biomarkers.
Features
- Diamond‑based NV‑center sensors that detect magnetic signatures of biomarkers with sub‑pico‑molar sensitivity
- Optical readout system that translates quantum spin states into measurable fluorescence signals
- Compact assay modules compatible with standard laboratory equipment and workflows
- Real‑time data acquisition and analysis software for quantitative reporting
- Non‑destructive measurement technique preserving sample integrity for downstream assays